By using the Pap with HPV DNA as a combined primary screening method for women age 30 and older, physicians are able to:

• Identify women who are at greatest risk for cervical disease or cancer
• Identify women who may have a persistent infection that can be about 300 times more likely to develop HSIL ^6,7
• Offer appropriate and effective follow-up,^2,3 since the combined Pap with HPV DNA test is more sensitive in determining the presence of disease than the Pap test alone.^5,8

For additional information

Pap with HPV DNA flyer

HPV Patient Information Brochure  (Spanish version)

References

Test Menu
Gynecologic Pap Test, Liquid-based Preparation (Image-guided) and Human Papillomavirus (HPV) Profile, Hybrid Capture II®, High-risk (Test 199123)

Gynecologic Pap Test, Liquid-based Preparation and Human Papillomavirus (HPV) Profile, Hybrid Capture II®, High-risk (Test 195050)

Additional Resources
LabCorp reports all cervical/cytology specimens in accordance with the “2001 Consensus Guidelines for the Management of Women with Cervical Cytology Abnormalities” printed in JAMA on April 24, 2002 (JAMA, Vol. 287, No.16, p2120-2128).

Algorithms for the guidelines have been published in the ASCCP’s Journal of Lower Genital Tract Disease. To view the algorithms, click here.

www.theHPVtest.com

The Next Improvement in Cervical Cancer Detection – Image-guided cytology

LabCorp offers image-guided cytology, the latest improvement in cervical cancer detection. LabCorp uses the Cytyc ThinPrep® Imaging System that combines human review with the power of an interactive computer imaging system.

Why select image-guided cervical cytology?

• A statistically significant improvement of 6.4% in sensitivity to 82% for ASC-US+¹
• Equivalent sensitivity for LSIL+ and HSIL+¹
• Statistically significant improvement of 0.2% in specificity to 99.6% for HSIL+¹
• Every slide has expert human review combined with the power of an interactive computer imaging system¹
• Scientific innovation reduces eyestrain and microscope fatigue, yielding improved diagnostic confidence in Pap results

Reference

1. The ThinPrep® Imaging System. Boxborough, Mass: Cytyc Corporation; 2004. Package insert.

Additional Information

Image-guided flyer

LabCorp’s Pap Test Patient Information Service
This convenient and time saving feature allows patient access to certain Pap test result information. Available on-line or through a dedicated toll-free telephone number, physicians can instruct their patients to visit the Web site or call and check on the status and/or result of their Pap test. Only final results that are within normal limits are available to the patient. Patients with abnormal results are advised to contact their physician during their physician’s regular business hour for more information and follow-up care.

By providing a direct mechanism for result status inquiry, the Pap Test Patient Information Service is beneficial for both physician and patient.

The LabCorp Pap Test Patient Information Service Offers

Convenience - The Web site and toll-free telephone number are available 24 hours a day, 7 days a week.
Security - Results are secure and confidential, accessible only with a patient’s unique identifiers.
Efficiency - As patients can access results at their convenience, the physician’s office staff is less likely to be interrupted by result status inquiries.
According to users, patients find the service user friendly because it’s easy to enter the requested information and follow prompts.

For additional information for physician clients, or to register for the service as a physician client, please contact your local LabCorp representative.

References for Pap with HPV DNA Testing

1. American Cancer Society. Overview: Cervical Cancer. How many women get cancer of the cervix? www.cancer.org.
2. Saslow D, Runowicz CD, Solomon D, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin. 2002; 52(6):342-362.
3. ACOG Committee on Practice Bulletins. ACOG Practice Bulletin: clinical management guidelines for obstetrician-gynecologists. Number 45, August 2003. Cervical cytology screening (replaces committee opinion 152, March 1995). Obstet Gynecol. 2003 Aug; 102(2):417-427.
4. Cuzick J, Szarewski A, Cubie H, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet. 2003; 362:1871-1876.
5. Lorincz A, Richart R. Human papillomavirus DNA testing as an adjunct to cytology in cervical screening programs. Arch Pathol Lab Med. 2003; 127: 959-968.
6. Bory JP, Cucherousset J, Lorenzato M, et al. Recurrent human papillomavirus infection, detected with the Hybrid Capture II assay, selects women with normal cervical smears at risk for developing high grade cervical lesions. A longitudinal study of 3,091 women. Int J Cancer. 2002; 102:519-525.
7. Liaw K-L,Glass AG, Manos MM, et al. Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous ntraepithelial lesions. J Nat Cancer Inst. 1999; 91(11):954-960.
8. Clavel C, Masure M, Bory J-P, et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Brit J Cancer. 2001; 89(12):1616-1623.